Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$59.20M

FY 2025 · Annual

Investing Cash Flow

-$73.45M

FY 2025 · Annual

Financing Cash Flow

$142.01M

FY 2025 · Annual

+71.6% YoY

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$60.9M
+ D&A$804.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$276.0K
+ Other Non-Cash$619.0K
= Operating Cash Flow-$59.2M
- Capex-$2.3M
= Free Cash Flow-$61.5M

Analysis

FY2025 free cash flow is -$61.5M. FCF conversion is 101.0% of net income. Operating cash flow was -$59.2M, with capex of -$2.3M. The largest bridge item is Capex at -$2.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
SC 13GSC 13G filingNov 13, 2026
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
3/A3/A filingOct 8, 2026

Does ATTO generate free cash flow?

Attovia Therapeutics, Inc. (ATTO) generated -$61.51M of free cash flow in fiscal 2025.

How much operating cash flow does ATTO produce?

Operating cash flow was -$59.20M, before capital expenditures of $2.31M.